/ABSTACT The Bioinformatics Core will provide services that are vital to many of the projects with in the SPORE in Prostate Cancer, including the application and development of statistical and computational techniques to process next-generation sequencing data from a variety of applications. The Core can apply standard processing algorithms and pipelines to a large number of samples. Additionally, the personnel of this Core have the expertise to create and deploy custom methods and applications as needed by the SPORE researchers. Members of the Core can leverage their experience in processing the large amount of genomic data at Memorial Sloan Kettering Cancer Center (MSKCC) to provide SPORE projects with state-of-the-art- applications with very little development time or effort; thus, greatly reducing the time and cost required for individual projects to develop their own analysis pipelines.
The specific aims of the Bioinformatics Core are:
Aim 1. To develop and provide state-of-the-art genomic analysis pipelines for: ? the detection of variants in targeted-DNA assays, MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) and whole exome sequence (WES). This pipeline will detect both single nucleotide changes and small insertion deletions for both somatic- and germline-variant calling scenarios. ? DNA copy number analysis, which can measure both total copy number changes and allele-specific copy number, including loss of heterozygosity (LOH).
Aim 2 : To facilitate the sharing of data generated in the SPORE research projects and enable collaboration of integrative analysis via the MSKCC cBioPortal by collecting, formatting, and importing data generated by these research projects into the cBioPortal.

Public Health Relevance

The Bioinformatics Core forms an integral part of the SPORE in Prostate Cancer as it directly supports the timely conduct of research of SPORE projects. The centralization of various bioinformatics services is designed to streamline requests of SPORE investigators to Core personnel with particular areas of expertise, therefore ensuring that services are provided in an efficient manner and with the highest quality. The Core also carries out research and development to identify new bioinformatic methods and rapidly works to implement and deploy these new techniques to make state-of-the-art computational pipelines available to the research groups in the SPORE and at Memorial Sloan Kettering Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092629-16
Application #
9148026
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2001-09-14
Project End
2021-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
16
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Puca, Loredana; Bareja, Rohan; Prandi, Davide et al. (2018) Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun 9:2404
Currall, Benjamin B; Chen, Ming; Sallari, Richard C et al. (2018) Loss of LDAH associated with prostate cancer and hearing loss. Hum Mol Genet 27:4194-4203
Armenia, Joshua; Wankowicz, Stephanie A M; Liu, David et al. (2018) The long tail of oncogenic drivers in prostate cancer. Nat Genet 50:645-651
Chen, Yu; Chi, Ping (2018) Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. J Hematol Oncol 11:78
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Audenet, François; Vertosick, Emily A; Fine, Samson W et al. (2018) Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer. J Urol 199:961-968
Hugosson, Jonas; Godtman, Rebecka Arnsrud; Carlsson, Sigrid V et al. (2018) Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 52:27-37
Kohestani, Kimia; Chilov, Marina; Carlsson, Sigrid V (2018) Prostate cancer screening-when to start and how to screen? Transl Androl Urol 7:34-45
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Kim, Kwanghee; Watson, Philip A; Lebdai, Souhil et al. (2018) Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. Clin Cancer Res 24:2408-2416

Showing the most recent 10 out of 505 publications